Evidence map›Paper›PMID 30673918›Full record

ArticleClinical and experimental medicine2019

Serum miR-122 levels correlate with diabetic retinopathy.

Nina Pastukh, Ari Meerson, Dorina Kalish, Hanin Jabaly, Arnon Blum

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Epigenetic Mechanisms in Type 2 Diabetes Retinopathy: A Systematic Review.International journal of molecular sciences · 2021
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Liquid Biopsy: A Game Changer for Type 2 Diabetes.International journal of molecular sciences · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nina PastukhVascular Biology Research Laboratory, Baruch Padeh Medical Center and Faculty of Medicine in the Galilee, Bar Ilan University, Safed, Israel.
Ari MeersonMIGAL Galilee Research Institute and Tel Hai Academic College, Kiryat Shmona, Israel.
Dorina KalishDepartment of Ophthalmology, Baruch Padeh Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, 15208, Ramat Gan, Israel.
Hanin JabalyDepartment of Ophthalmology, Baruch Padeh Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, 15208, Ramat Gan, Israel.
Arnon BlumDepartment of Medicine, Baruch Padeh Medical Center, and Azrieli Faculty of Medicine, Bar Ilan University, 15208, Ramat Gan, Israel. ABlum@poria.health.gov.il.ORCID http://orcid.org/0000-0002-7467-4222
Bar-Ilan University · ILTel Hai Academic College · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy is the most severe ocular complication of diabetes and may lead to visual disability and blindness. Proliferative diabetic retinopathy (PDR) is characterized by ischemia-induced neovascularization with associated complications. An association was established between the presence of PDR, cardiovascular disease, and mortality among patients with type 1 diabetes mellitus and type 2 diabetes mellitus in epidemiological studies. However, the mechanism underlying increased cardiovascular risk in patients with PDR is still unknown. In recent years, a group of miRNAs has been linked to the pathology of diabetes mellitus. Besides, miRNAs in biofluids such as serum have been suggested as potential minimally invasive biomarkers of diabetes and vascular complications. This was a prospective study that recruited 40 human subjects: 10 healthy subjects, 10 with diabetes but without retinopathy (NDR), 10 with diabetic non-proliferative retinopathy (NPDR), and 10 with proliferative diabetic retinopathy (PDR). To examine whether serum miRNAs show altered levels at different stages of diabetic retinopathy, seven specific miRNA candidates (miR-126-3p, miR-130a-3p, miR-21-1, let-7f-5p, miR-122, miR-30c and miR-451a) were measured by qRT-PCR in RNA isolated from sera of all subjects. miR-122 levels increased in parallel with retinopathy severity: from healthy controls to NDR and from NDR to NPDR. However, when the disease progressed to PDR a marked decrease in miR-122 level was noted. This decrease was significant both compared to NPDR samples (p = 0.016) and to all non-PDR samples (p = 0.0002). Additionally, a positive trend was observed comparing miR-122 levels and the number of endothelial progenitor cells in the sera of all subjects. A significant increase in miR-122 was found in patients with diabetic retinopathy that may be related to its role in preventing angiogenesis and proliferation. The dramatic decline in patients with PDR may represent an inhibition or exhaustion of the anti-angiogenic anti-proliferative defense system. Further studies are needed to understand whether miRNA-122 has a role in the pathogenesis of diabetic retinopathy.

Indexed as

AdultAgedAged, 80 and overDiabetic RetinopathyFemaleHumansMaleMicroRNAsMiddle AgedProspective StudiesReal-Time Polymerase Chain ReactionSerumMicroRNAsMIRN122 microRNA, humanDiabetes mellitusDiabetic reinopathymiRNA 122

Identifiers

PMID30673918
OpenAlexW2911498362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.